Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations

CompletedOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

August 1, 2023

Study Completion Date

January 25, 2024

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
OTHER

Non-interventional

Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.

Trial Locations (13)

Unknown

University Hospital Sassari, Sassari

Mater Dei Hospital, Valletta

Changi General Hospital, Singapore

Singapore General Hospital, Singapore

Ljubljana University Medical Centre, Ljubljana

Hanyang University Guri Hospital, Hanyang

Seoul St. Mary's Hospital, Seoul

Ulsan University Hospital, Ulsan

Hospital University de Torrecárdenas, Almería

University Hospital Vall d'Hebron, Barcelona

Hospital Inmaculada HLA, Granada

HU Virgen de las Nieves, Granada

Hospital Universitario de La Ribera, Valencia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Respiratory Effectiveness Group

OTHER

NCT04360226 - Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations | Biotech Hunter | Biotech Hunter